How has the subcutaneous immunoglobulin (scig) market evolved, and where is it heading next?
The subcutaneous immunoglobulin (SCIG) market size has grown rapidly in recent years. It will grow from $12.72 billion in 2024 to $14.52 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to the increased prevalence of immunodeficiency disorders, rise in the patient preference for home-based care, enhanced therapeutic efficacy, growth in the awareness and diagnosis rates, growth in the favorable reimbursement policies.
The subcutaneous immunoglobulin (SCIG) market size is expected to see rapid growth in the next few years. It will grow to $24.29 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, Innovations in formulations, and Innovations in SCIG.
Get Your Free Sample of The Global Subcutaneous Immunoglobulin (SCIG) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp
What are the key drivers behind the rapid expansion of the subcutaneous immunoglobulin (scig) market?
The increase in the prevalence of secondary immunodeficiency diseases is expected to propel the growth of the subcutaneous immunoglobulin market going forward. Secondary immunodeficiency diseases are conditions with a reduced or compromised immune system caused by sources other than the immune system itself. The prevalence of secondary immunodeficiency diseases is driven by various factors such as aging populations, the use of immunosuppressive treatments, and environmental toxins. Subcutaneous immunoglobulin therapy provides antibodies to help strengthen the weakened immune system, especially in chronic disorders such as HIV or autoimmune diseases, thereby preventing infections and supporting immunological function during treatment. For instance, in October 2023, according to the UK Health Security Agency, a UK-based government agency, reported 3,805 new HIV diagnoses in England in 2022, representing a 22% rise from the previous year. Therefore, the increase in the prevalence of secondary immunodeficiency diseases is driving the growth of the subcutaneous immunoglobulin market.
What is the segmentation for the subcutaneous immunoglobulin (scig) market?
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM
Order your report now for swift delivery
Who are the most influential companies in the subcutaneous immunoglobulin (scig) market?
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc
What are the most influential trends expected to drive the subcutaneous immunoglobulin (scig) market forward?
Major companies operating in the subcutaneous immunoglobulin market are developing subcutaneous human-klhw, a unique formulation containing human immune globulins (Ig) that strengthens the immune system. Subcutaneous human-klhw is used for subcutaneous administration, developed for treating primary immunodeficiency diseases in human body. For instance, in March 2022, Grifols S.A., a Spain-based pharmaceutical company, launched XEMBIFY 20% subcutaneous immunoglobulin (SCIG). It is specifically designed to treat primary immunodeficiency, meeting a significant medical need for people with weakened immune systems. XEMBIFY is a ready-to-use formulation that simplifies the treatment process and increases patient convenience. It is stable at room temperature for up to 24 months, avoiding the need for refrigeration during storage and transportation, which can be extremely useful in a variety of healthcare settings.
What are the major regional insights for the subcutaneous immunoglobulin (scig) market, and which region holds the top position?
North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Subcutaneous Immunoglobulin (SCIG) Market Report 2025 Offer?
The subcutaneous immunoglobulin (scig) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy in which the medication is delivered under the skin, rather than into a vein. This method allows for slower absorption of the medication, reducing the risk of side effects compared to intravenous administration. SCIG is used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
